Clinical Pathways

  • Embracing Hope, Naming the Uncomfortable, and Empowering the Patient in Palliative Care

    Embracing Hope, Naming the Uncomfortable, and Empowering the Patient in Palliative Care

    Our CMO Dr. Monica Soni, and American Cancer Society's Chief Patient Officer Dr. Arif Kamal discuss current challenges and the future of effective palliative care.

    Watch Video
  • When Equality and Health Equity Diverge

    When Equality and Health Equity Diverge

    Treating patients the same isn't always the path to improved outcomes, writes our associate chief medical officer.

    Read Article
  • ×

    First Name
    Last Name
    Company Name
    Thank you!
    Error - something went wrong!
  • Targeting Overuse, Misuse and Underuse in Cardiovascular Care: Why Health Plans Need a Comprehensive Strategy

    Targeting Overuse, Misuse and Underuse in Cardiovascular Care: Why Health Plans Need a Comprehensive Strategy

    Learn key strategies for health plans to reduce three types of inappropriate use in cardiovascular care.

    Read Insight Brief
  • Panel Discussion: Oncology Care Reimagined

    Panel Discussion: Oncology Care Reimagined

    Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.

    Watch Video
  • Let's Go
  • Episode 7: Underuse In Cardiology Is Under-Appreciated. How Do We Change That?

    Episode 7: Underuse In Cardiology Is Under-Appreciated. How Do We Change That?

    Learn why underuse is a major problem and how we might tackle it

    Listen to podcast
  • Specialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler Says

    Specialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler Says

    Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.

    Read External Article
  • Episode 6: Why Don't More Cardiology Patients Get Optimal Medication Therapy?

    Episode 6: Why Don't More Cardiology Patients Get Optimal Medication Therapy?

    GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.

    Listen to podcast
  • Episode 5: Will COVID-19 Change What Is Considered Appropriate Use in Cardiology?

    Episode 5: Will COVID-19 Change What Is Considered Appropriate Use in Cardiology?

    Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?

    Listen to Podcast
  • Health Systems' Rare Rejection of Alzheimer's Drug Sparks Questions About FDA Approvals

    Health Systems' Rare Rejection of Alzheimer's Drug Sparks Questions About FDA Approvals

    Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.

    Read Article
  • Specialty Pharmacies Grapple with Assessing Costs and Value of Oncology Therapies

    Specialty Pharmacies Grapple with Assessing Costs and Value of Oncology Therapies

    Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.

    Read Article
  • Learn More
  • Hitting the Brakes on Fast-Tracked Drugs

    Hitting the Brakes on Fast-Tracked Drugs

    The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.

    Read Article
  • CMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting

    CMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting

    New Century Health CMO, Dr. Andrew Hertler, shares his thoughts on the recent FDA meetings to review the merits of approved cancer drugs.

    Watch Video
  • Traditional UM Programs Can't Move the Needle in Cardiology Care. Here's What Does.

    Traditional UM Programs Can't Move the Needle in Cardiology Care. Here's What Does.

    Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.

    Read Article
  • Episode 2: Choice Paralysis

    Episode 2: Choice Paralysis

    The therapeutic landscape in oncology is vast and everchanging, marked by a dramatic pace of innovation and new approvals. In this complicated specialty, how can payers and providers keep up?

    Read Article
  • Learn More
  • Introduction to Leading Causes: A Podcast by New Century Health

    Introduction to Leading Causes: A Podcast by New Century Health

    In this podcast series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.

    Listen to Podcast
  • Cardiovascular Clinical Pathways Program at New Century Health

    Cardiovascular Clinical Pathways Program at New Century Health

    Our senior medical director speaks with Journal of Clinical Pathways about preventing inappropriate use in cardiology.

    Read External Article
  • Can Clinical Pathways Help Combat Health Care Disparities?

    Can Clinical Pathways Help Combat Health Care Disparities?

    A new research effort aims to gauge whether certain groups of patients receive high-value therapies at lower rates than others.

    Read Article
  • Pathways, Portals and Persuasion: Reining in an Overused Cancer Agent

    Pathways, Portals and Persuasion: Reining in an Overused Cancer Agent

    NCH's approach to more appropriate use of myeloid growth factor provides a playbook for how to change prescribing patterns.

    Read Article
  • How Real-World Evidence Can Transform High-Value Oncology Pathways

    How Real-World Evidence Can Transform High-Value Oncology Pathways

    Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical oncology pathways.

    Read Article
  • High-Value Clinical Pathways Help Illinois Cancer Practice Reduce Drug Spend

    High-Value Clinical Pathways Help Illinois Cancer Practice Reduce Drug Spend

    Recent journal article details how NCH and Cancer Care Specialists of Illinois teamed up to slow growth in drug spend.

    Read Article
  • loading
    Loading More...